Current Landscape in the Systemic Treatment of Hepatobiliary Cancers: From Neoadjuvant Strategies to Advanced Disease

Gain expert perspectives on novel immunotherapy combinations and targeted therapies for hepatocellular carcinoma and biliary tract cancers through downloadable slidesets.

Share

Program Content

Activities

FAQ: HCC Treatment
Experts Answer Frequently Asked Questions on the Contemporary Management of Hepatocellular Carcinoma
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: January 03, 2022

Expires: January 02, 2023

Activities

Treating Advanced HCC
Setting New Therapeutic Standards in Advanced HCC
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 12, 2021

Expires: November 11, 2022

Treating Early HCC
Systemic Therapy Combinations for Early or Intermediate-Stage HCC: Current Evidence and Ongoing Trials
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 12, 2021

Expires: November 11, 2022

Treating BTC
Targeted Therapies for Biliary Tract Cancers
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 12, 2021

Expires: November 11, 2022

<i>EP</i>: Hepatobiliary Ca Tx
ExpressPoints
Current Landscape in the Systemic Treatment of Hepatobiliary Cancers
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: November 18, 2021

Expires: November 17, 2022

Faculty

cover img faculity

Richard S. Finn, MD

Assistant Professor of Medicine
Division of Hematology-Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

cover img faculity

Amit G. Singal, MD, MS

Chief of Hepatology
Medical Director
, Liver Tumor Program
Professor, Department of Internal Medicine
UT Southwestern Medical Center
Dallas, Texas

cover img faculity

Mark Yarchoan, MD

Assistant Professor
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins
Baltimore, Maryland

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Genentech, a member of the Roche Group